Accounting, Finance & Bookkeeping Services
FDA approves Vertex cystic fibrosis drug, shares jump By Anna Yukhananov and Bill Berkrot (article courtesy of Reuters) Health regulators approved Vertex Pharmaceuticals' Kalydeco, the first drug designed to treat the underlying cause of cystic fibrosis, a rare genetic disease. The … [Read More...]
U.S. FDA guidance on biosimilars may be imminent By Lewis Krauskopf Article Courtesy of: NEW YORK (Reuters) The U.S. Food and Drug Administration appears to be on the verge of issuing long-awaiting guidelines for the development of generic versions of complex biotechnology medicines. The … [Read More...]
Massachusetts will take the global stage next June when the BIO International Convention returns to Boston. Article Courtesy of: Massachusetts Biotechnology Council The convention, the world’s largest gathering of industry stakeholders, will come to the Boston Convention and Exhibition … [Read More...]
Jobless Claims, Factory Data Suggest Recovery Picking Up Article Courtesy of: Reuters Government reports on weekly jobless claims and manufacturing activity in the Northeast for December released Thursday offered fresh evidence the U.S. economic recovery is picking up steam. Inflation … [Read More...]
What to Look for from the Fed in 2012 Article Courtesy of: Danielle Kurtzleben | US News The Fed is treading water for now, but how long will it last? In a statement about December's meeting of the Federal Open Market Committee, officials decided to maintain existing policies, … [Read More...]
Interesting article below on the potential effects of the upcoming Obamacare Supreme Court decision on the pharma/device industries – J.R. by Sean Riley (Courtesy of Omaha Republican Examiner) By all accounts Obamacare is in its infancy stage at this point, and we’re already seeing massive transformations in our country. Private insurance companies are raising their prices,…
Read More
FDA approves Vertex cystic fibrosis drug, shares jump By Anna Yukhananov and Bill Berkrot (article courtesy of Reuters) Health regulators approved Vertex Pharmaceuticals’ Kalydeco, the first drug designed to treat the underlying cause of cystic fibrosis, a rare genetic disease. The Food and Drug Administration said on Tuesday Kalydeco was effective in treating people with the life-shortening…
Read More
Genzyme’s road to recovery New Framingham plant to target drug shortages By Marie Szaniszlo | Article Courtesy of The Boston Herald Photo by Ted Fitzgerald Genzyme will begin shipping its Fabrazyme drug by the end of this month from its Framingham biotech factory, which has secured federal regulatory approval, the company announced yesterday. The nod…
Read More
Massachusetts will take the global stage next June when the BIO International Convention returns to Boston. Article Courtesy of: Massachusetts Biotechnology Council The convention, the world’s largest gathering of industry stakeholders, will come to the Boston Convention and Exhibition Center June 18-21, 2012. MassBio will lead the Massachusetts presence at the show, by managing the…
Read More
U.S. FDA guidance on biosimilars may be imminent By Lewis Krauskopf Article Courtesy of: NEW YORK (Reuters) The U.S. Food and Drug Administration appears to be on the verge of issuing long-awaiting guidelines for the development of generic versions of complex biotechnology medicines. The FDA still plans to release the guidance by the end of…
Read More
Safe places to stash cash in an uncertain world Article Courtesy of: Sheyna Steiner | Bankrate.com Investors have many options when the return of principal is more important than the return on principal. But in today’s ultra-low yield environment, the price of safety is enormous. That’s why savers and investors may need to abandon the…
Read More
What to Look for from the Fed in 2012 Article Courtesy of: Danielle Kurtzleben | US News The Fed is treading water for now, but how long will it last? In a statement about December’s meeting of the Federal Open Market Committee, officials decided to maintain existing policies, including keeping the federal funds rate at…
Read More
Jobless Claims, Factory Data Suggest Recovery Picking Up Article Courtesy of: Reuters Government reports on weekly jobless claims and manufacturing activity in the Northeast for December released Thursday offered fresh evidence the U.S. economic recovery is picking up steam. Inflation also remained in check last month, with wholesale prices rising modestly, a separate report showed.…
Read More
Kroeker Gets Cranky With the AICPA’s Private Company Accounting Ideas Article by: Adrienne Gonzalez Apparently SEC chief accountant James Kroeker does not appreciate the AICPA’s disapproval of the FAF’s new proposal to set up a Private Company Standards Improvement Council, calling the disapproval “a clear threat to the independence of the FAF.” Accounting Today has…
Read More
Kroeker Gets Cranky With the AICPA’s Private Company Accounting Ideas Article by: Adrienne Gonzalez Apparently SEC chief accountant James Kroeker does not appreciate the AICPA’s disapproval of the FAF’s new proposal to set up a Private Company Standards Improvement Council, calling the disapproval “a clear threat to the independence of the FAF.” Accounting Today has…
Read More
Jobless Claims, Factory Data Suggest Recovery Picking Up Article Courtesy of: Reuters Government reports on weekly jobless claims and manufacturing activity in the Northeast for December released Thursday offered fresh evidence the U.S. economic recovery is picking up steam. Inflation also remained in check last month, with wholesale prices rising modestly, a separate report showed.…
Read More
What to Look for from the Fed in 2012 Article Courtesy of: Danielle Kurtzleben | US News The Fed is treading water for now, but how long will it last? In a statement about December’s meeting of the Federal Open Market Committee, officials decided to maintain existing policies, including keeping the federal funds rate at…
Read More
Safe places to stash cash in an uncertain world Article Courtesy of: Sheyna Steiner | Bankrate.com Investors have many options when the return of principal is more important than the return on principal. But in today’s ultra-low yield environment, the price of safety is enormous. That’s why savers and investors may need to abandon the…
Read More
U.S. FDA guidance on biosimilars may be imminent By Lewis Krauskopf Article Courtesy of: NEW YORK (Reuters) The U.S. Food and Drug Administration appears to be on the verge of issuing long-awaiting guidelines for the development of generic versions of complex biotechnology medicines. The FDA still plans to release the guidance by the end of…
Read More
Social - Rocha Accounting